8-K: Breeze Holdings Acquisition Corp. to Merge with YD Biopharma in $700 Million Deal

Breeze Holdings Acquisition Corp. has announced a definitive agreement to merge with YD Biopharma, a clinical-stage biopharmaceutical company, in a deal that values the combined entity at nearly $700 million.

Summary

• Breeze Holdings Acquisition Corp. and YD Biopharma Limited have entered into a merger agreement.
• The combined company is expected to have an enterprise value of approximately $700 million.
• YD Biopharma focuses on cancer prevention diagnostics and exosome-based therapeutics.
• The merger is expected to close by early 2025, with the combined company listing on the Nasdaq Capital Market.
• YD Biopharma has obtained patents and technology for pancreatic cancer detection and is acquiring licenses for breast cancer detection.
• The aggregate consideration to be received by the equity holders of YD Biopharma is based on a pre-transaction equity value of $647,304,110.
• The exchange ratio will be equal to $647,304,110 divided by the number of fully-diluted shares of YD Biopharma Common Stock outstanding as of the Closing, further divided by an assumed value of Pubco Ordinary Shares of $10.00 per share.

Sentiment

Score: 8

Explanation: The document presents a positive outlook on the merger, highlighting the potential of YD Biopharma's technology and the benefits of the transaction. The management commentary is optimistic, and the transaction is expected to provide capital for growth. However, there are also risks and uncertainties associated with the transaction, which temper the overall sentiment.

Positives

• YD Biopharma has a diverse portfolio of solutions, including ophthalmology, cancer diagnostics, and nutritional products.
• The company has established strategic partnerships with Novartis, EG BioMed, and 3D Global Biotech.
• YD Biopharma possesses proprietary technology and a strong IP portfolio.
• The company is targeting large and underserved markets with significant growth potential.
• YD Biopharma has a strong leadership team with expertise in biotech and finance.

Negatives

• The merger is subject to customary closing conditions, regulatory and stockholder approvals.
• The transaction is not expected to close until early 2025.
• The combined company will have an estimated post-transaction enterprise value of $694 million, consisting of an estimated equity value of $715 million, $21.0 million in cash and no debt.
• Cash proceeds raised will consist of Breezes $10.1 million cash in trust (before redemptions and payment of any transaction expenses) and $15 million in anticipated new capital.

Risks

• The ability of the parties to complete the proposed transaction within the anticipated timeframe or at all.
• The failure to realize the anticipated benefits of the proposed transaction.
• The risk that the proposed transaction may not be completed by Breeze's business combination deadline.
• The failure to satisfy the conditions to the consummation of the proposed transaction.
• The occurrence of any event that could give rise to the termination of the merger agreement.
• The effect of the announcement or pendency of the proposed transaction on YD Biopharma's business relationships.
• The outcome of any legal proceedings related to the merger agreement or YD Biopharma's products.
• The ability to maintain the listing of the combined company's securities on the Nasdaq Capital Market.
• Potential volatility in the price of Breeze's securities due to various factors.
• The inability of YD Biopharma to successfully develop and commercialize its products and services.
• The risk that the combined company may never achieve or sustain profitability.
• The costs of the proposed transaction.

Future Outlook

The combined company is expected to be listed on the Nasdaq Capital Market and will use the proceeds from the transaction to expand production and continue development, approval and launch of new technologies.

Management Comments

• Dr. Ethan Shen stated, 'I'm pleased to announce the next phase of our strategy as we embark on a public listing in the U.S. through the proposed business combination with Breeze.'
• Dr. Shen also said, 'Since our founding in 2013, we've made significant strides in expanding our capabilities through organic innovation, licensing agreements, and notable strategic partnerships.'
• J. Douglas Ramsey, Ph.D., commented, 'We are highly optimistic about the proposed business combination with YD Biopharma, a company that we believe is a true outlier in the biotech industry with strong growth potential in a variety of healthcare markets.'

Industry Context

This announcement comes amid a busy period for biotech and pharmaceutical IPOs, indicating strong investor interest in the sector. The merger allows YD Biopharma to access public markets and capital for further development and commercialization of its technologies.

Comparison to Industry Standards

• The document references recent successful biotech IPOs such as MBX Biosciences, Bicara Therapeutics, and Zenas BioPharma, which all experienced positive trading activity post-IPO.
• YD Biopharma's technology for pancreatic cancer detection claims higher accuracy (~92%) and early detection rates compared to current market solutions (50-60%).
• YD Biopharma's breast cancer detection technology is described as more sensitive, accurate, lower cost, and easier to operate than other methods.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders of Breeze and YD Biopharma will receive shares in the combined company.
• Employees of YD Biopharma will become employees of the combined company.
• Customers of YD Biopharma will have access to a broader range of products and services.
• The combined company will have access to capital for further development and commercialization.

Next Steps

• The parties will seek regulatory and stockholder approvals.
• The combined company will be listed on the Nasdaq Capital Market.
• YD Biopharma will expand production and continue development, approval and launch of new technologies.
• The parties will work to close the transaction by early 2025.

Key Dates

Keywords

Merger, Biopharma, Acquisition, Cancer Diagnostics, Exosome Therapeutics, Nasdaq, Biotechnology, Healthcare, Pharmaceuticals, Early Detection